Open Label Trial to Assess Iressa in Prostate Cancer Patients
A study to assess the activity of Iressa in patients who's prostate cancer has recurred, and who have rising PSA levels
Prostate Cancer
DRUG: Gefitinib
Serum Prostate Specific Antigen, Monthly
Duration of PSA decline, Monthly|Safety variables, Monthly|Time to Progression, Every 3 months
A study to assess the activity of Iressa in patients who's prostate cancer has recurred, and who have rising PSA levels